Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Mebeverine→

Mebeverine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
3625-06-7
Molecular formula
C25H35NO5
Molecular weight
429.5 g/mol
Drug class
Musculotropic gastrointestinal antispasmodic
Mechanism of action
Acts directly on gastrointestinal smooth muscle without materially affecting normal gut motility. The exact mechanism is not fully known; proposed contributing actions include altered ion-channel permeability, noradrenaline reuptake inhibition, local anaesthetic activity and weak antimuscarinic/phosphodiesterase effects.
Indications / reported uses
  • Symptomatic treatment of irritable bowel syndrome
  • Other functional bowel conditions associated with colicky abdominal pain, cramps, spastic constipation, diarrhoea and flatulence, according to product information

Sources: UK SmPC — Mebeverine 135 mg tablets (updated 9 Apr 2026) · UK SmPC — Mebeverine MR 200 mg capsules · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Musculotropic gastrointestinal antispasmodic

Mechanism of action

Acts directly on gastrointestinal smooth muscle without materially affecting normal gut motility. The exact mechanism is not fully known; proposed contributing actions include altered ion-channel permeability, noradrenaline reuptake inhibition, local anaesthetic activity and weak antimuscarinic/phosphodiesterase effects.

General use cases

  • Symptomatic treatment of irritable bowel syndrome
  • Other functional bowel conditions associated with colicky abdominal pain, cramps, spastic constipation, diarrhoea and flatulence, according to product information

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Mebeverine Environmental Risk Assessment (ERA) (the Mebeverine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.